MicroRNA-107 alleviates ferroptosis-mediated acute kidney injury by regulating the PI3K/Akt/mTOR pathway

Pengfei Zhao1, Zhenghua Wu1, Hua Chen2

  • 1Organ transplant center, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.

BMC Nephrology
|December 17, 2025
PubMed
Abstract

Insights

Low miR-107 levels are found in acute kidney injury (AKI). Upregulating miR-107 inhibits ferroptosis, suggesting a protective role in AKI pathogenesis.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biochemistry

Background:

  • Acute kidney injury (AKI) pathogenesis requires further elucidation of mechanistic pathways and biomarkers.
  • Investigating microRNA-107 (miR-107) expression and its role in ferroptosis-mediated AKI is crucial.

Purpose of the Study:

  • To examine miR-107 expression levels in patients with AKI.
  • To elucidate the molecular mechanisms by which miR-107 regulates ferroptosis in AKI.

Main Methods:

  • Serum miR-107 levels were quantified using qRT-PCR in 30 AKI patients and 30 healthy controls.
  • In vitro (HK-2 cells) and in vivo (AKI mice model) studies were conducted to assess miR-107's effect on ferroptosis.
  • Biomarkers of oxidative stress (malondialdehyde, reactive oxygen species, glutathione) and the PI3K/Akt/mTOR pathway were analyzed.

Main Results:

  • miR-107 expression was significantly down-regulated in AKI patients' serum and in AKI/ferroptosis models.
  • miR-107 upregulation reduced ferroptosis markers (MDA, ROS) and increased protective markers (GSH) in vitro and in vivo.
  • miR-107 expression correlated with the PI3K/Akt/mTOR pathway in ferroptosis.

Conclusions:

  • miR-107 is a potential diagnostic biomarker for AKI due to its decreased expression.
  • miR-107 inhibits ferroptosis, indicating a protective role in mitigating AKI progression.